Bio-Rad Expands Droplet Digital PCR Offering Through Strategic Acquisition and Platform Rollout
MWN-AI** Summary
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a leader in life sciences and diagnostics, has announced the launch of four new Droplet Digital™ PCR (ddPCR™) platforms, marking a significant expansion in their digital PCR offerings. This development comes on the heels of Bio-Rad's acquisition of Stilla Technologies, a digital PCR developer. The new platforms include the QX Continuum™ and the QX700™ series, which complement Bio-Rad's established QX200™ and QX600™ ddPCR systems.
The expanded product range consists of over 400,000 assays, making Bio-Rad’s portfolio one of the most comprehensive in the digital PCR domain. Features of these new systems include advanced multiplexing capabilities, high precision, and industry-leading absolute quantification. The QX Continuum™ system is tailored for translational research, boasting a qPCR-like workflow that combines ease of use with high performance. It supports multiplexing in four colors and manages up to eight different thermal profiles on a single plate.
The QX700™ series is designed for various applications, including academic research, environmental testing, and quality control in biopharma. These instruments can process over 700 samples per day with minimal input volume and feature user-friendly software for data interpretation.
Jim Barry, EVP and President of Bio-Rad’s Life Science Group, emphasized that these new platforms enhance Bio-Rad's position in the genomics and applied sciences markets by offering unmatched workflow simplicity and throughput. Overall, the acquisition and subsequent launch demonstrate Bio-Rad's commitment to advancing digital PCR technology and broadening its market presence in life science research and clinical diagnostics.
For more information, visit bio-rad.com/dropletdigitalPCR.
MWN-AI** Analysis
Bio-Rad Laboratories’ recent expansion of its Droplet Digital PCR (ddPCR) product line through the acquisition of Stilla Technologies presents a strategic opportunity for investors focused on the biotechnology sector. With the launch of advanced platforms like the QX Continuum and QX700 series, Bio-Rad significantly enhances its market position in genomic research and clinical diagnostics.
The QX Continuum ddPCR system, notable for its user-friendly interface and versatile multiplexing capabilities, stands out as an appealing choice for translational research applications. Meanwhile, the QX700 series, designed for high-volume processing and diverse research applications, allows users to conduct extensive sample analyses with greater efficiency. With over 400,000 assays available, Bio-Rad now provides the most comprehensive suite of digital PCR tools, enhancing its competitive edge.
Investors should note that the demand for precision and high-throughput solutions in life sciences is growing, driven by increasing investments in genomic research and personalized medicine. Bio-Rad’s newly launched instruments may cater to burgeoning needs in oncology, infectious disease, and genetic research, thus widening its user base among academic institutions, hospitals, and biopharmaceutical companies.
However, potential investors must also consider inherent risks. Factors like global economic fluctuations, regulatory challenges, and competitive pressures could impact Bio-Rad’s performance. Continued innovation is key, and the company must consistently meet market needs to sustain growth.
In summary, Bio-Rad’s strategic acquisition and subsequent product rollouts are likely to strengthen its leadership in the ddPCR market. Investors should consider an optimistic outlook on BIO, remaining mindful of the accompanying risks in this dynamic sector of biotechnology. Overall, it may represent a promising investment for those looking to capitalize on advancements in life sciences and diagnostics.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced the launch of four new Droplet Digital™ PCR (ddPCR™) platforms. The newly introduced instruments include Bio-Rad’s QX Continuum™ ddPCR system along with the QX700™ series of ddPCR platforms acquired as part of the company’s recently completed acquisition of digital PCR developer Stilla Technologies.
Together with Bio-Rad’s existing line of QX200™ and QX600™ ddPCR systems, the expanded product portfolio, including over 400,000 assays, offers the most comprehensive line of digital PCR products for life science research and diagnostic applications. The end-to-end solutions feature industry-leading absolute quantification, high precision, and advanced multiplexing capabilities, combined with streamlined and simplified workflows.
“With this launch, our expanded portfolio of instruments, reagents, software, and services extends Bio-Rad’s presence in the genomics research and applied science markets and strengthens our leadership in droplet digital PCR solutions,” said Jim Barry, EVP and President of Bio-Rad’s Life Science Group. “The newly introduced platforms complement Bio-Rad's existing QX ddPCR portfolio and offer our customers unparalleled workflow simplicity and throughput capabilities across the full spectrum of digital PCR applications including oncology, infectious disease, and genetic research.”
The QX Continuum™ ddPCR system is designed for translational research applications. It features qPCR-like workflow offering simplicity, performance and flexibility in an all-in-one configuration with four-color multiplexing and up to eight discrete thermal profiles per plate.
The QX700™ series consists of three new ddPCR instruments designed for academic research, environmental testing, cell and gene therapy, and biopharma quality control workflows. The systems enable seven-color multiplexing, capacity to process over 700 samples per day, with minimal input volume, continuous loading capability, and easy-to-use software for streamlined data interpretation.
To learn more about the new QX Continuum and QX700 series, as well as Bio-Rad’s comprehensive portfolio of digital PCR instruments, consumables, and assays visit: bio-rad.com/dropletdigitalPCR
BIO-RAD, QX CONTINUUM, QX700, QX600, QX200, DROPLET DIGITAL, and DDPCR are trademarks of Bio-Rad Laboratories, Inc. in certain jurisdictions.
About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B) is a leader in developing, manufacturing, and marketing a broad range of products for the life science research and clinical diagnostics markets. Based in Hercules, California, Bio-Rad operates a global network of research, development, manufacturing, and sales operations with approximately 7,700 employees and $2.6 billion in revenues in 2024. Our customers include universities, research institutions, hospitals, and biopharmaceutical companies, as well as clinical, food safety and environmental quality laboratories. Together, we develop innovative, high-quality products that advance science and save lives. To learn more, visit bio-rad.com .
Forward-Looking Statements
This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding our products and our expectations about our products. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "plan", "believe," "expect," "anticipate," "may," "will," "intend," "estimate," "continue," or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include risks relating to our international operations, global economic and geopolitical conditions, tariffs or other trade barriers, reductions in government funding or capital spending of our customers, our ability to develop and market new or improved products, our ability to compete effectively, international legal and regulatory risks, supply chain risks, and product quality and liability issues. For further information regarding our risks and uncertainties, please refer to the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operation" in Bio-Rad's public reports filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. Bio-Rad cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250707879192/en/
Investor Contact:
Edward Chung, Investor Relations
510-741-6104
ir@bio-rad.com
Media Contact:
Anna Gralinska, Corporate Communications
510-741-6643
cc@bio-rad.com
FAQ**
How will the launch of the new QX Continuum™ and QX700™ ddPCR platforms impact Bio-Rad Laboratories Inc. Cl B BIOB's competitive positioning in the life sciences market?
What are the expected revenue contributions from the newly acquired ddPCR platforms for Bio-Rad Laboratories Inc. Cl B BIOB in the upcoming fiscal year?
How does Bio-Rad Laboratories Inc. Cl B BIOB plan to leverage its expanded portfolio to enhance customer engagement and loyalty in the genomics research sector?
What risks does Bio-Rad Laboratories Inc. Cl B BIOB foresee in the rollout of its new ddPCR products, and how does it intend to mitigate those risks?
**MWN-AI FAQ is based on asking OpenAI questions about Bio-Rad Laboratories Inc. Class A (NYSE: BIO).
NASDAQ: BIO
BIO Trading
11.5% G/L:
$277.42 Last:
471,754 Volume:
$274.72 Open:
